You are here

Biosimilars Could Cut U.S. Health Tab by $54 Billion in a Decade

Regulatory rules are the key to achieving future savings, RAND says

Introducing "biosimilar" versions of complex biologic drugs used to treat illnesses such as cancer and rheumatoid arthritis could cut health care spending in the United States by $54 billion over the next decade, according to a new analysis from the RAND Corporation.

The savings estimate is about 20% larger than a similar analysis done by RAND researchers three years ago, representing both improved analysis methods and rapid growth in spending for biologics overall.

"Biologics account for the fastest-growing segment of prescription drug spending, but biosimilars have the potential to help slow some of the increase," said Andrew Mulcahy, lead author of the study and a policy researcher at RAND, a nonprofit research organization. "However, there remain many important industry, regulatory, and policy decisions to be made that will influence whether such savings are realized."

Biologics are complex, protein-based drugs manufactured in living systems. They include insulin, monoclonal antibodies to block inflammation in rheumatoid arthritis, and a range of drugs to treat cancer, multiple sclerosis, and other serious diseases.

While biologics are important treatments for many conditions, they often are expensive, and patient copays for the treatments can be several thousand dollars per year. While 1% to 2% of the nation's population is treated with a biologic each year, the drugs accounted for 38% of prescription drug spending in 2015. In addition, biologics accounted for 70% of the growth in prescription drug spending in the U.S. between 2010 and 2015.

Biosimilars are very similar to already approved "reference" biologics in terms of potency, safety and efficacy, but are manufactured by different companies. Biosimilars can be approved for marketing by the FDA after the manufacturer of the reference biologic enjoys several years of patent and exclusivity protection.

The Biologics Price Competition and Innovation Act, enacted as part of the 2010 Patient Protection and Affordable Care Act, authorized the FDA to create a new approval pathway for biosimilars with the goal of promoting competition. This new pathway is faster and less costly for biosimilar developers.

RAND researchers developed their estimate of savings from biosimilars by examining other studies that have examined the issue, reviewing the sales history of more than 100 biologic drugs, and examining the brief experience of the one biosimilar drug that has been marketed in the U.S.

RAND researchers estimate that that biosimilars will cut spending on biologics by about 3% over the next decade. The range of the new savings estimate given reasonable ranges of key assumptions—like the price of biosimilars versus reference biologics and biosimilar market share—varied from $24 billion to $150 billion from 2018 through 2027.

While expected to produce less-dramatic savings than an earlier generation of less-complex generic drugs, the introduction of biosimilars into the U.S. marketplace is expected to increase competition and drive down prices, resulting in savings for patients, health care payers, and taxpayers. Lower costs also could improve access to biologic drugs, which could lead to higher spending overall unless the treatments helped lower hospitalizations or other costs.

"The actual savings hinge on the evolving competitive landscape in the pharmaceutical industry, regulatory decisions, and insurer efforts to promote biosimilar uptake through payment rates and other strategies," Mulcahy said. "Future research will be needed as more biosimilars come to market to see whether savings are realized and who benefits from any reductions in spending."

Source: RAND Corporation; October 23, 2017.

More Headlines

In study, progression-free survival was superior to Rituxan-based therapy
This is the first new medicine for this population in two decades
First agency-approved treatment for pediatric and adult patients with MPS VII
FDA clears NSS-2 Bridge in an effort to reduce symptoms
FDA establishes a pathway to speed approval for similar tests
Acorda Therapeutics hits pause on trial enrollment for tozadenant
New indication marks first adjuvant treatment after nephrectomy
First respiratory biologic with an eight-week maintenance dosing schedule
Under guidelines, nearly half of U.S. population will be diagnosed with hypertension